AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. (AIM) on March 4, 2026, covering events occurring on March 4 and March 6, 2026. The filing details the completion of a previously announced Rights Offering and the creation of a new series of convertible preferred stock.
Key Financial Metrics and Capital Structure
The filing reports the following specific financial data related to the Rights Offering:
- Gross Proceeds: Approximately $1,800,000 raised from the sale of units.
- Units Sold: 1,842 units.
- Components per Unit:
- 1 share of Series G Convertible Preferred Stock (Stated Value: $1,000).
- 2,000 Class G Warrants (Total warrants issued: 3,684,000).
- Conversion/Exercise Price: $1.00 per share for both the Series G Preferred Stock and Class G Warrants.
- Warrant Expiration: Five years from the date of issuance.
The filing text does not provide clear values for revenue, net profit, operating cash flow, gross margins, total debt, or liquidity ratios outside of the proceeds from this specific transaction.
Material Changes and Corporate Actions
Significant changes to the company's capital structure include:
- Series G Preferred Stock Creation: On March 4, 2026, the Company filed a Certificate of Designation creating 12,000 authorized shares of Series G Convertible Preferred Stock. 1,842 shares were issued in the offering.
- Conversion Limitations: Holders cannot convert shares if it would result in beneficial ownership exceeding 4.99% of outstanding common stock, unless the holder provides notice to increase the limit (up to a maximum of 9.99%).
- Dividend and Liquidation Rights: Series G holders receive dividends on an "as-if-converted" basis and share pari passu with common stockholders in liquidation. There are no mandatory redemption rights.
- Warrant Agency Agreement: On March 6, 2026, the Company entered into an agreement with Equiniti Trust Company, LLC to act as warrant agent for the Class G Warrants.
Outlook, Risks, and Management Commentary
The filing confirms the successful closing of the Rights Offering on March 6, 2026. Management commentary is limited to the execution of the transaction and the terms of the new securities. No specific forward-looking guidance regarding future revenue, earnings, or operational milestones is provided in this document. The primary risk disclosed relates to the dilution of existing shareholders upon the conversion of the Series G Preferred Stock and the exercise of the Class G Warrants.
Key Facts for Investor Verification
- Verify the total number of common shares outstanding immediately prior to this offering to calculate the potential dilution impact of the 1,842 shares of Series G Preferred Stock and 3,684,000 Class G Warrants.
- Confirm the use of the approximately $1.8 million in gross proceeds as disclosed in the prospectus supplement referenced in the filing.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution adjustment mechanisms and exceptions to the 4.99% beneficial ownership limitation.
- Check subsequent filings for any changes in the Company's cash position or liquidity status following the receipt of these proceeds.